| abstract |
The present invention relates to compositions and methods for administering a fully human post-translational human (HuPTM) therapeutic VEGF trap (VEGF-Trap HuPTM ) to a human subject diagnosed with ocular disease, by for example, age-related macular degeneration (AMD) or a condition or cancer associated with neovascularization, such as metastatic colon cancer, and indicated for treatment with therapeutic mAb. The administration can be advantageously carried out by gene therapy, for example by administration of a viral vector, preferably AAV8 or the AAV.7m8 variant, or of another DNA expression construct encoding VEGF-Trap HuPTM. to a patient (human subject) diagnosed with an eye condition or a cancer indicated for treatment with the VEGF trap to create a permanent depot in a tissue or organ of the patient that continuously supplies VEGF-Trap HuPTM , that is, that is, a human glycosylated transgenic product. Alternatively, VEGF-Trap HuPTM , for example, produced in a culture of cultured human cells, for example in immortalized retinal or liver cells, can be administered to the patient for the treatment of eye disease or cancer. |